JPH0637508B2 - 抗生物質Ａ４０９２６複合体およびその純粋な因子ＰＡ、ＰＢ、Ａ、ＢおよびＢｏ - Google Patents

抗生物質Ａ４０９２６複合体およびその純粋な因子ＰＡ、ＰＢ、Ａ、ＢおよびＢｏ

Info

Publication number
JPH0637508B2
JPH0637508B2 JP60226671A JP22667185A JPH0637508B2 JP H0637508 B2 JPH0637508 B2 JP H0637508B2 JP 60226671 A JP60226671 A JP 60226671A JP 22667185 A JP22667185 A JP 22667185A JP H0637508 B2 JPH0637508 B2 JP H0637508B2
Authority
JP
Japan
Prior art keywords
antibiotic
factor
eluent
ppm
nujol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP60226671A
Other languages
English (en)
Japanese (ja)
Other versions
JPS61148188A (ja
Inventor
エンリコ・セルバ
ルチアーノ・ガスタルド
グラツイア・ベレツタ
アンジエロ・ボルギ
ベス・ピー・ゴールドスタイン
ビツトリオ・アリオリ
ジヨバンニ・カツサニ
フランチエスコ・パレンテイ
Original Assignee
グルポ・レペチツト・エス・ピ−・エイ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by グルポ・レペチツト・エス・ピ−・エイ filed Critical グルポ・レペチツト・エス・ピ−・エイ
Publication of JPS61148188A publication Critical patent/JPS61148188A/ja
Publication of JPH0637508B2 publication Critical patent/JPH0637508B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • C07K9/006—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence being part of a ring structure
    • C07K9/008—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence being part of a ring structure directly attached to a hetero atom of the saccharide radical, e.g. actaplanin, avoparcin, ristomycin, vancomycin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P1/00—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes
    • C12P1/06—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes by using actinomycetales
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P5/00—Preparation of hydrocarbons or halogenated hydrocarbons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/03—Actinomadura

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Saccharide Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP60226671A 1984-10-11 1985-10-11 抗生物質Ａ４０９２６複合体およびその純粋な因子ＰＡ、ＰＢ、Ａ、ＢおよびＢｏ Expired - Fee Related JPH0637508B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB8425685 1984-10-11
GB848425685A GB8425685D0 (en) 1984-10-11 1984-10-11 Antibiotic a 40926 complex

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP5265554A Division JP2572937B2 (ja) 1984-10-11 1993-09-30 新規菌株

Publications (2)

Publication Number Publication Date
JPS61148188A JPS61148188A (ja) 1986-07-05
JPH0637508B2 true JPH0637508B2 (ja) 1994-05-18

Family

ID=10568022

Family Applications (2)

Application Number Title Priority Date Filing Date
JP60226671A Expired - Fee Related JPH0637508B2 (ja) 1984-10-11 1985-10-11 抗生物質Ａ４０９２６複合体およびその純粋な因子ＰＡ、ＰＢ、Ａ、ＢおよびＢｏ
JP5265554A Expired - Lifetime JP2572937B2 (ja) 1984-10-11 1993-09-30 新規菌株

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP5265554A Expired - Lifetime JP2572937B2 (ja) 1984-10-11 1993-09-30 新規菌株

Country Status (22)

Country Link
US (1) US4935238A (enExample)
EP (1) EP0177882B1 (enExample)
JP (2) JPH0637508B2 (enExample)
KR (1) KR940009280B1 (enExample)
AT (1) ATE49215T1 (enExample)
AU (1) AU599308B2 (enExample)
CA (1) CA1317900C (enExample)
DE (1) DE3575145D1 (enExample)
DK (1) DK161092C (enExample)
ES (1) ES8609352A1 (enExample)
FI (1) FI81117C (enExample)
GB (1) GB8425685D0 (enExample)
GR (1) GR852442B (enExample)
HU (1) HU194317B (enExample)
IE (1) IE58708B1 (enExample)
IL (1) IL76596A (enExample)
MY (1) MY100880A (enExample)
NO (1) NO164111C (enExample)
NZ (1) NZ213775A (enExample)
PH (1) PH23013A (enExample)
PT (1) PT81288B (enExample)
ZA (1) ZA857697B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011157381A (ja) * 2002-11-18 2011-08-18 Vicuron Pharmaceuticals Inc 細菌感染の治療のためのダルババンシンの投与方法

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8531846D0 (en) * 1985-12-30 1986-02-05 Lepetit Spa Antibiotic a 40926 mannosyl aglycon
GB8608798D0 (en) * 1986-04-11 1986-05-14 Lepetit Spa Recovery of glycopeptide antibiotics from aqueous solutions
GB8608809D0 (en) * 1986-04-11 1986-05-14 Lepetit Spa Antibiotic
DK363587A (da) * 1986-07-30 1988-01-31 Smithkline Beckman Corp Antibiotika og fremstilling heraf under anvendelseaf actinomadura parvosata
GB8621912D0 (en) * 1986-09-11 1986-10-15 Lepetit Spa Increasing ratio of components of anti-biotic complex
GR871488B (en) * 1986-10-10 1987-11-12 Lepetit Spa New antibiotics
US5135857A (en) * 1987-07-03 1992-08-04 Gruppo Lepetit S.P.A. Process for the preparation of de-mannosyl teicoplanin derivatives
PH27266A (en) * 1989-03-14 1993-05-04 Fujisawa Pharmaceutical Co WS7622, A,B,C and D substances and pharmaceutical composition containing same
DE69117304T2 (de) * 1990-12-05 1996-08-29 Lepetit Spa 38-decarboxy-38-hydroxymethylderivate von teicoplaninantibiotika, und verfahren zu deren herstellung
KR100209971B1 (ko) 1991-03-27 1999-07-15 클라우디오 쿼르타 항생제 a 40926 에스테르 유도체
US5606036A (en) * 1991-03-27 1997-02-25 Gruppo Lepetit Spa Antibiotic A 40926 ester derivatives
US5750509A (en) * 1991-07-29 1998-05-12 Gruppo Lepetit S.P.A. Amide derivatives of antibiotic A 40926
DK0836619T3 (da) * 1995-07-05 2004-12-06 Aventis Bulk S P A Oprensning af dalbaheptid antibiotika ved hjælp af isoelektrisk fokusering
EP0912604B1 (en) 1996-04-23 2001-11-14 Biosearch Italia S.p.A. Improved chemical process for preparing amide derivatives of antibiotic A 40926
RU2124895C1 (ru) * 1998-05-28 1999-01-20 Головкина Любовь Павловна Противопаразитарная мазь "авермектиновая"
EP1413626A1 (en) * 2002-10-23 2004-04-28 Vicuron Pharmaceuticals, Inc. Genes and proteins for the biosynthesis of the glycopeptide antibiotic A40926
US20060074014A1 (en) 2002-11-18 2006-04-06 Vicuron Pharmaceuticals Inc. Dalbavancin compositions for treatment of bacterial infections
US7119061B2 (en) * 2002-11-18 2006-10-10 Vicuron Pharmaceuticals, Inc. Dalbavancin compositions for treatment of bacterial infections
CN110183519B (zh) * 2019-05-06 2023-04-11 大邦(湖南)生物制药有限公司 一种达巴万星关键中间体a40926的分离纯化方法
CN110156876A (zh) * 2019-05-25 2019-08-23 聊城大学 一种适合工业化生产的高纯度a40926b0制备方法
US12545702B2 (en) * 2019-06-13 2026-02-10 Regeneron Pharmaceuticals, Inc. Methods for removing undesired components during multistage chromatographic processes
CN110940763B (zh) * 2019-12-19 2022-07-26 宜昌东阳光生化制药有限公司 分离纯化达巴万星前体a40926的方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4195079A (en) * 1979-01-31 1980-03-25 Pfizer Inc. New polycyclic ether antibiotic
CA1183789A (en) * 1981-08-04 1985-03-12 Kiyoshi Isono Antibiotic 76-11, process for the production thereof, anticoccidiosis agent and domestic animals growth accelerator comprising the same as an effective ingredient
US4578271A (en) * 1982-05-24 1986-03-25 Fujisawa Pharmaceutical Co., Ltd. Biologically active WS 6049 substances, a process for the production thereof and their pharmaceutical compositions
GR78648B (enExample) * 1982-07-26 1984-09-27 Bristol Myers Co

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011157381A (ja) * 2002-11-18 2011-08-18 Vicuron Pharmaceuticals Inc 細菌感染の治療のためのダルババンシンの投与方法

Also Published As

Publication number Publication date
ATE49215T1 (de) 1990-01-15
EP0177882B1 (en) 1990-01-03
HU194317B (en) 1988-01-28
FI81117C (fi) 1990-09-10
JP2572937B2 (ja) 1997-01-16
NO854018L (no) 1986-04-14
IL76596A0 (en) 1986-02-28
KR860003342A (ko) 1986-05-23
ZA857697B (en) 1986-07-30
PT81288A (en) 1985-11-01
MY100880A (en) 1991-05-16
DK161092C (da) 1991-11-18
DK457385D0 (da) 1985-10-08
HUT39480A (en) 1986-09-29
KR940009280B1 (ko) 1994-10-06
IE58708B1 (en) 1993-11-03
PH23013A (en) 1989-03-03
NZ213775A (en) 1989-03-29
AU4819585A (en) 1986-04-17
US4935238A (en) 1990-06-19
EP0177882A3 (en) 1987-05-27
AU599308B2 (en) 1990-07-19
NO164111B (no) 1990-05-21
PT81288B (pt) 1987-10-20
CA1317900C (en) 1993-05-18
EP0177882A2 (en) 1986-04-16
FI853914A0 (fi) 1985-10-08
IL76596A (en) 1992-05-25
DE3575145D1 (de) 1990-02-08
DK457385A (da) 1986-04-12
ES8609352A1 (es) 1986-09-01
ES547766A0 (es) 1986-09-01
FI81117B (fi) 1990-05-31
GR852442B (enExample) 1986-02-03
DK161092B (da) 1991-05-27
GB8425685D0 (en) 1984-11-14
IE852489L (en) 1986-04-11
FI853914L (fi) 1986-04-12
NO164111C (no) 1990-08-29
JPH06225757A (ja) 1994-08-16
JPS61148188A (ja) 1986-07-05

Similar Documents

Publication Publication Date Title
JPH0637508B2 (ja) 抗生物質Ａ４０９２６複合体およびその純粋な因子ＰＡ、ＰＢ、Ａ、ＢおよびＢｏ
KR950010460B1 (ko) 항생 물질 a40926 만노실 아글리콘의 제조방법
KR960013074B1 (ko) 글리코펩티드 항생물질
EP0010421B1 (en) Mixture of antibiotics designated by a-21978, process for its production, their pharmaceutical compositions and producing microorganism
US4868171A (en) Antibiotic A 40926 N-acylaminoglucuronyl aglycons and antiobiotic A 40926 aglycon
NL8001982A (nl) Antibiotisch werkzame stof en werkwijze ter bereiding en toepassing van deze stof en farmaceutisch preparaat, dat deze stof bevat.
KR0165684B1 (ko) 항생물질 ge 2270 인자 b1, b2, c1, c2, d1, d2, e 및 t
EP1285928B1 (en) Antibiotics tripropeptins and process for producing the same
JPH0763387B2 (ja) テイコプラニン‐様誘導体
US4742045A (en) Glycopeptide antibiotics
JPH0213392A (ja) ペプチド抗生物質
EP0254999B1 (en) Antibiotic a 42867 and the addition salts thereof
EP0675900B1 (en) Antibiotics ge 37468 a, b and c
EP0255299A2 (en) Glycopeptide antibiotics
US4816559A (en) Biologically active peptides TAN-866
JPH0430400B2 (enExample)
NZ227946A (en) Actinomadura strain atcc 39727 useful for producing antibiotic a 40926

Legal Events

Date Code Title Description
R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees